The Nanocurcumin Reduces Appetite in Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): A Double-Blind Randomized Placebo-Controlled Clinical Trial

Document Type: Research Paper


1 Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences (IC-TUMS), Tehran, Iran

2 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran, Department of Toxicology–Pharmacology, Faculty of Pharmacy, Pharmaceutical Science Branch, Islamic Azad University (IAUPS), Tehran, Iran

3 National Iranian Oil Company (NIOC) Central Hospital, Tehran, Iran

4 Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

5 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran

6 Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran


Objective(s): Various beneficial effects of curcumin have been seen specially as anti-inflammator and antioxidant agent. However, until now no human studies have been done on curcumin’s role in control of appetite. So, the present study was done to determine the effect of nanocurcumin on appetite in obese Non-Alcoholic Fatty Liver Disease (NAFLD) patients.
Materials and Methods: This study was done in the central hospital of Oil Company, Tehran. According to the eligiblity criteria, 84 NAFLD patients with obesity were enrolled. The patients were devided randomly to 2 equal groups (nanocurcumin and placebo, 80 mg/day with meals, follow-up monthly for 3 months). In addition, lifestyle advises were presented. The general questionnaire, appetite sensations (using visual analogue scales [VAS]), , weight and height at the beginning and the end of the study were recorded
Results: The mean age and body mass index (BMI) were 41.8(±5.6), 30.67(±2.14)and 42.5(±6.2)yrs and 30.75(±2.35)kg/m2 for nanocurcumin and placebo groups respectively. The baseline characteristics and dietary intakes were similar between patients, exception for energy, total fat, saturated fat, monounsaturated fatty acid, vitamins D, B1, B6, and folate (DFE). The appetite significantly reduced according to both unadjusted and adjusted analysis models.
Conclusion: This study was the first assess of nanocurcumin’s role in control of appetite among obese NAFLD patients. Overall results showed the nanocurcumin supplementation reduced appetite significantly. However, determining the potential role of curcumin in managing of NAFLD- and obesity-related conditions need further study.


1. Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017; 57(13): 2889-2895.
2. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006; 78(18): 2081-2087.
3. Noorafshan A, Ashkani-Esfahani S. A review of therapeutic effects of curcumin. Curr Pharm Des. 2013; 19(11): 2032-2046.
4. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol. 2016; 68(3): 223-229.
5. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of Non‐alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo‐controlled Trial. Phytother Res. 2016; 30(9): 1540-1548.
6. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15(1): 11.
7. Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(7): 1756.
8. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. World J Gastroenterol. 2005; 184(2): 291-318.
9. Suzuki K, Jayasena CN, Bloom SR. The gut hormones in appetite regulation. J Obes. 2011; 2011.
10. Henkin RI, Levy LM, Fordyce A. Taste and smell function in chronic disease:: A review of clinical and biochemical evaluations of taste and smell dysfunction in over 5000 patients at The Taste and Smell Clinic in Washington, DC. Am J Otolaryngol. 2013; 34(5): 477-489.
11. Owen J. Weight control and appetite—A genetic perspective. Clin Nutr. 1990; 9(5): 291-293.
12. Kang KS, Yahashi S, Azuma M, Sakashita A, Shioda S, Matsuda K. Effect of intraperitoneal injection of curcumin on food intake in a goldfish model. J Mol Neurosci. 2011; 45(2): 172-176.
13. Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, et al. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol. BMJ open. 2017; 7(7): e016914.
14. Daneshi-Maskooni M, Keshavarz SA, Mansouri S, Qorbani M, Alavian SM, Badri-Fariman M, et al. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. Trials. 2017; 18(1): 260.
15. Gregersen N, Møller B, Raben A, Kristensen S, Holm L, Flint A. Determinants of appetite ratings: the role of age, gender, BMI, physical activity, smoking habits, and diet/weight concern. Food Nutr Res. 2011; 55(1): 7028.
16. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. 2012; 69(1): 65-70.
17. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. The molecular targets and therapeutic uses of curcumin in health and disease: Springer; 2007. 1-75.
18. Oelkrug C, Lange CM, Wenzel E, Fricke S, Hartke M, Simasi J, et al. Analysis of the tumoricidal and anti-cachectic potential of curcumin. Anticancer Res. 2014; 34(9): 4781-4788.
19. Selmanovic S, Beganlic A, Salihefendic N, Ljuca F, Softic A, Smajic E. Therapeutic Effects of Curcumin on Ultrasonic Morphological Characteristics of Liver in Patients with Metabolic Syndrome. Acta Inform Med. 2017; 25(3): 169.
20. Di Pierro F, Bressan A, Ranaldi D, Rapacioli G, Giacomelli L, Bertuccioli A. Potential role of bioavailable curcumin in weight loss and omental adipose tissue decrease: preliminary data of a randomized, controlled trial in overweight people with metabolic syndrome. Preliminary study. Eur Rev Med Pharmacol Sci. 2015; 19(21): 4195-4202.
21. Atkin SL, Katsiki N, Derosa G, Maffioli P, Sahebkar A. Curcuminoids Lower Plasma Leptin Concentrations: A Meta‐analysis. Phytother Res. 2017; 31(12): 1836-1841.
22. Ciftci O, Tanyildizi S, Godekmerdan A. Protective effect of curcumin on immune system and body weight gain on rats intoxicated with 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD). Immunopharmacol Immunotoxicol. 2010; 32(1): 99-104.
23. Farhat G, Drummond S, Al‐Dujaili EA. Polyphenols and Their Role in Obesity Management: A Systematic Review of Randomized Clinical Trials. Phytother Res. 2017; 31(7): 1005-1018.